The New Bioeconomic Battleground: How AI, Data, and Biotechnology Are Rewriting Global Strategy
A Conversation Between Christopher P. Skroupa, Skytop Editor-in-Chief, and Edward H. You, Founder and Principal of EHY Consulting LLC / May 29, 2026
Edward H. You is Founder and Principal of EHY Consulting LLC, where he advises organizations on the strategic implications of converging biological, digital, industrial, and governance systems. A former FBI Supervisory Special Agent and national security expert, he served in senior advisory and leadership roles across the U.S. government, including assignments supporting the Office of the Director of National Intelligence (ODNI) and policy engagements involving the White House National Security Council.
Over the course of his career, Edward worked at the intersection of emerging technologies, biotechnology, data ecosystems, and strategic risk, helping organizations understand the evolving implications of technological convergence, infrastructure interdependence, and global competitiveness.
His current work focuses on how advances in artificial intelligence, biotechnology, advanced biomanufacturing, agriculture, and digital infrastructure are reshaping resilience, economic competitiveness, and long-term strategic capability. He examines how nations and industries are integrating data, operational systems, and translational infrastructure into adaptive learning ecosystems that accelerate innovation, scalability, and market influence.
Edward is widely recognized for his systems-level analysis of the evolving bioeconomy, including the strategic significance of biological and operational data, AI-enabled industrial transformation, standards development, and the convergence of health, agricultural, and manufacturing ecosystems. His advisory work emphasizes practical governance approaches that preserve innovation, strengthen resilience, and support trusted collaboration in an increasingly interconnected global environment.
Christopher Skroupa: You’ve argued that the global bioeconomy has changed dramatically over the past decade. What, in your view, is the most important shift shaping today’s strategic environment?
Edward You: The most consequential shift is the evolution of biological and operational data from a static research resource into a strategic learning asset. Increasingly, value is not derived simply from collecting data, but from the ability to continuously integrate, analyze, operationalize, and learn from it across interconnected systems.
At a broader level, the emergence of the bioeconomy reflects an acknowledgment that biotechnology is no longer confined to the life sciences sector. Advances in biotechnology, artificial intelligence, advanced manufacturing, agriculture, energy, and digital infrastructure are increasingly influencing every critical infrastructure domain. Organizations and nations that can effectively integrate these domains into adaptive learning ecosystems may gain long-term advantages in innovation, scalability, resilience, and strategic agility.
Christopher Skroupa: China is often discussed in the context of biotechnology and data ecosystems. From your perspective, what distinguishes its broader approach to integrating biotechnology, data, and industrial capability?
Edward You: China increasingly appears to view biotechnology as a foundational component of long-term economic competitiveness, industrial modernization, and strategic resilience. What distinguishes its approach is the intentional integration of biotechnology, artificial intelligence, advanced manufacturing, digital infrastructure, and operational deployment into broader national development strategies.
This direction is becoming more visible in policy priorities associated with China’s emerging 15th Five-Year Plan, including AI-enabled biomanufacturing, advanced therapeutics, industrial biotechnology, and next-generation infrastructure development. The focus is not simply scientific discovery, but building interconnected ecosystems that can accelerate translational capability, industrial scaling, and continuous operational learning.
Christopher Skroupa: What real-world pressures are driving China’s focus on biotechnology and data?
Edward You: China’s focus on biotechnology and AI appears increasingly tied to long-term structural challenges and strategic planning. These include demographic shifts, food security, healthcare demands, supply chain resilience, environmental pressures, and the growing energy and computational requirements associated with advanced digital infrastructure.
Biotechnology is attractive because it can influence multiple sectors simultaneously. AI-enabled agriculture, advanced therapeutics, industrial biomanufacturing, and alternative bio-based production systems all have the potential to improve efficiency, scalability, and resilience across interconnected infrastructures. More broadly, this reflects a growing recognition that biotechnology is becoming an enabling layer across critical infrastructure sectors rather than remaining confined to the life sciences alone.
Christopher Skroupa: What changed with China’s regulatory reforms and their impact on drug development?
Edward You: China’s regulatory reforms helped reduce friction between research, clinical development, manufacturing, and commercialization. That acceleration mattered because biotechnology increasingly depends on continuous learning cycles rather than isolated scientific breakthroughs.
In areas such as CAR-T and advanced therapeutics, the scale of clinical activity generates valuable operational and clinical datasets that can continuously refine manufacturing processes, treatment protocols, and platform development. The strategic advantage increasingly comes from the ability to operationalize learning at scale and translate innovation into deployable capability.
Christopher Skroupa: What concerns you most regarding U.S. vulnerabilities?
Edward You: Historically, biotechnology vulnerabilities were often viewed primarily through the lens of biothreats and potential bioweapons concerns. While those issues remain important, that framework alone does not fully capture the realities emerging from the convergence of biotechnology, artificial intelligence, advanced manufacturing, and data infrastructure.
Today, biotechnology increasingly operates through globally distributed ecosystems involving research collaborations, clinical trials, manufacturing partnerships, and cross-border data flows. The strategic challenge is less about isolated access to data and more about how clinical, operational, and manufacturing data are integrated into adaptive learning systems that continuously refine capability, scalability, and resilience over time. Many existing governance and policy frameworks were simply not designed for this level of technological and infrastructure convergence.
Christopher Skroupa: You have described China’s evolution from “fast follower” to “fast adopter.” What enabled that transition?
Edward You: Historically, China was often viewed primarily as a manufacturing powerhouse with more limited capacity for original innovation. The convergence of artificial intelligence, biotechnology, and large-scale data ecosystems has helped shift that perception by accelerating China’s ability to operationalize, scale, and refine emerging technologies across interconnected infrastructures.
In some emerging “greenfield” domains, this creates opportunities to establish early leadership positions, shape technical standards and specifications, and drive domestic adoption at scale. Over time, participation in international standards bodies can help translate those approaches into broader global frameworks that influence interoperability, supply chains, and future market positioning. Increasingly, strategic advantage comes not simply from invention, but from the ability to integrate, operationalize, scale, and standardize emerging capabilities.
Christopher Skroupa: You have spoken about China’s engagement in international standards bodies. Why does this matter?
Edward You: Standards increasingly influence how emerging technologies are integrated, scaled, and adopted across global markets. In many cases, the organizations and nations that help shape technical standards and interoperability frameworks may also influence future supply chains, infrastructure ecosystems, and market positioning.
China’s long-term focus on standards participation reflects a recognition that standards are not simply technical guidelines — they can become strategic mechanisms that shape how technologies are operationalized and adopted globally over time. Particularly in emerging greenfield areas tied to AI, biotechnology, and advanced manufacturing, standards development may increasingly influence competitive advantage and ecosystem leadership.
Christopher Skroupa: Agriculture plays a surprisingly large role in your analysis. Why?
Edward You: Agriculture is increasingly becoming a strategic infrastructure layer rather than simply a commodity sector. China’s emphasis on biotechnology reflects broader pressures tied to food security, resource constraints, supply chain resilience, and long-term energy security. Recent disruptions in global energy markets have further highlighted the importance of resiliency and alternative bio-based production systems.
Advances in biotechnology and AI are accelerating what many describe as “farm to fork, farm to fiber, and farm to fuel” ecosystems. Precision agriculture, biofuels, industrial bioproducts, satellite-enabled monitoring, and AI-driven optimization are increasingly linking agriculture to energy, manufacturing, logistics, and broader bioeconomic development. In this environment, agricultural systems are no longer operating independently — they are becoming integrated components of strategic industrial and infrastructure ecosystems.
Christopher Skroupa: What policy recommendations do you suggest?
Edward You: My focus is less on restriction and more on strategic alignment. The United States retains significant strengths in innovation, research, and entrepreneurship, but long-term competitiveness may increasingly depend on the ability to better integrate biotechnology, AI, manufacturing, agriculture, and data infrastructure into scalable operational ecosystems.
That includes strengthening biomanufacturing capacity, reducing friction between research and commercialization, improving visibility into cross-border data flows, supporting workforce development, treating agriculture as strategic infrastructure, and maintaining active participation in international standards development. The broader goal is to ensure the United States can translate innovation into resilient, deployable capability at scale.
Christopher Skroupa: How would you summarize your core message in one line?
Edward You: The convergence of artificial intelligence and biotechnology is accelerating what increasingly resembles a global biotech space race, where data serves as the fuel powering continuous learning, operational scaling, and strategic advantage. As a result, we need to fundamentally rethink how we assess risks, opportunities, competitiveness, and long-term bioeconomic security in an increasingly interconnected world